MSLN and neoplasm: Adachi et al. first demonstrated that CAR-T cells, specific for endogenous murine mesothelin, engineered to express IL-7 and CCL19 upon CAR stimulation, demonstrated significant anti-tumor effects in a subcutaneous, murine Pan02 PDAC model [181].